GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can Results From One Cell Type Apply to Another?

Not automatically. A benefit shown for one stem cell type does not establish that another cell type will provide the same benefit or carry the same risks. It may offer a reason to investigate a related treatment, but the treatment being offered needs evidence relevant to its own cells, manufacturing, dose, delivery route, condition, and patients. Even a close match does not guarantee that an individual patient will benefit.

If a clinic cites a successful study, the useful question is not simply whether it used “stem cells.” It is whether the study supports the particular product and use you are considering.

Can Results From One Cell Type Apply to Another?

Why Cell Types Are Not Interchangeable

“Stem cell” describes cells with different developmental abilities and normal roles. Embryonic stem cells are pluripotent: they can develop into the body’s different cell types. Adult stem cells have a more limited range. Blood-forming stem cells, for example, produce blood cells. Scientists can also reprogram adult cells to make induced pluripotent stem cells, which are used in research, including disease modeling and drug testing What are stem cells.

Sharing an umbrella term does not make two products interchangeable. A study of blood-forming cells cannot, by itself, establish the effectiveness of a mesenchymal stromal cell (MSC) injection. A laboratory finding also answers a different question from a study measuring symptoms, function, or survival in people.

Which Products Are Being Compared?

Product What the evidence describes What cannot be assumed
Blood-forming stem cells Transplants can restore blood-cell production after high-dose chemotherapy or radiation has destroyed blood-forming cells. They are used for selected cancers and blood disorders, including leukemia, lymphoma, and aplastic anemia Stem cell transplant. These established uses do not establish that a different cell product repairs cartilage or treats an unrelated disease.
Cultured mesenchymal stromal cells The ISCT’s 2006 laboratory criteria include plastic adherence, a specified surface-marker pattern, and differentiation into bone, fat, and cartilage cells under laboratory conditions 16923606. Meeting identity criteria does not prove clinical effectiveness or show that MSC products from different tissues or manufacturing processes are equivalent.
Cell-free products, such as exosome preparations These are not living-cell transplants. The FDA includes exosomes among products marketed as regenerative medicine therapies and warns about unapproved products and associated harms Important patient and consumer information about regenerative medicine therapies. Evidence for a living-cell treatment does not establish the effectiveness or safety of a cell-free preparation.

What Changes the Relevance of a Study?

  • Cell identity and tissue source. Check the exact product, not just a label such as MSCs or “stem cells.” Ask whether the study used the same source and how the cells were identified.
  • Donor relationship. Autologous means cells from the patient; allogeneic means cells from a donor. This comparison of autologous and allogeneic approaches provides background, not independent evidence that a treatment works.
  • Manufacturing. Compare isolation, culture expansion, storage, and quality testing. The same starting tissue is not enough to demonstrate product equivalence.
  • Dose, route, and schedule. An intravenous infusion, a joint injection, and a surgical implant are different procedures. Evidence from one route is not direct evidence for another.
  • Condition and patient group. Check diagnosis, severity, age, previous treatment, and accompanying care. A result in children with a transplant complication does not establish a result in adults with joint pain.

A mismatch does not prove that the proposed treatment cannot work. It means the cited study leaves a gap that needs supporting evidence and clinical justification.

What One MSC Approval Actually Shows

On December 18, 2024, the FDA approved Ryoncil (remestemcel-L-rknd), an allogeneic bone-marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. This is a complication of donor transplantation that has not responded adequately to steroid treatment. The FDA described Ryoncil as its first approved MSC therapy Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

The supporting study enrolled 54 pediatric patients after allogeneic blood-forming stem cell transplantation. It was prospective, multicenter, and single-arm, with no concurrent comparison group. The patients had Grade B to D disease, excluding Grade B disease limited to the skin, and had not received a second-line treatment before screening Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

The FDA reported a day-28 overall response rate of 70% (95% confidence interval, 56.4%–82.0%), including 30% complete responses and 41% partial responses. Those separately rounded percentages should not be added to replace the reported overall rate. Median response duration was 54 days, measured from the day-28 response until progression, new systemic treatment for acute graft-versus-host disease, or death Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

The recommended initial regimen is 2 million MSCs per kilogram per intravenous infusion, twice weekly for four consecutive weeks, for eight infusions. Further treatment depends on response. Common nonlaboratory adverse reactions, occurring in at least 20% of patients, included infections, fever, hemorrhage, edema, abdominal pain, and hypertension Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

These are response data for a particular product and population, not a general “stem cell success rate.” A single-arm study does not provide a randomized comparison with an alternative treatment, and a day-28 response is not synonymous with cure or lasting benefit. This approval does not authorize a different MSC product or an unrelated indication.

A Worked Comparison Before Accepting a Claim

Suppose an offer for an adult’s knee pain cites the Ryoncil study. This is an illustrative comparison, not a patient case or a report of clinical experience. In the FDA record, the patients were children with steroid-refractory acute graft-versus-host disease, the product was donor bone-marrow-derived MSCs, and the route was intravenous infusion. The measured response concerned that transplant complication, not knee pain or cartilage repair Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

For the knee-pain offer, ask for human evidence on the proposed product, route, and orthopedic condition. A shared MSC label does not bridge the differences. The FDA’s consumer information page, marked current as of April 8, 2024, states that regenerative medicine therapies had not been approved for orthopedic conditions, including osteoarthritis, disc disease, and knee or back pain. That dated statement is not a substitute for checking the current status of a specific product Important patient and consumer information about regenerative medicine therapies.

How Strong Is the Supporting Evidence?

  • Human outcomes. Laboratory differentiation and animal findings can guide research; they do not establish benefit in people. Look for outcomes relevant to patients, not only cell markers or imaging changes.
  • Study design. Was there a comparison group, random assignment, or blinded assessment? NCI explains that phase 1 studies focus on safety and dose, phase 2 studies also assess whether treatment appears to work, and phase 3 studies compare it with standard therapy. An early efficacy signal is not the same as a reliable comparative benefit How trials work.
  • Size and follow-up. How many patients contributed to the result, how precise was the estimate, and how long did benefit and safety monitoring last?
  • Harms. Ask what adverse events occurred and how complications would be managed. The FDA describes infection, unwanted immune reactions, and unintended tissue growth among concerns with unapproved regenerative products Important patient and consumer information about regenerative medicine therapies. This overview of safety questions in Japan offers background for discussing the proposed procedure.
  • Source of the claim. Read the study itself. Trial registration proves that a record exists, not that treatment works; PubMed indexing is not a quality verdict. A commercial summary is not independent confirmation.

Does a Japan Filing Establish Effectiveness?

No. For care governed by Japan’s Act on the Safety of Regenerative Medicine, the framework includes review of a provision plan by a certified committee and submission to the Ministry of Health, Labour and Welfare. These procedures should not be described as product approval or proof of clinical effectiveness En.

Regenerative medical products also have a separate marketing-approval framework involving PMDA review. It is the product and its authorized conditions of use that matter, not simply whether care is offered in Japan 0003.

The site’s regenerative medicine overview and registration and compliance explanation describe services and processes. They do not independently establish a treatment’s effectiveness.

Questions to Take to Your Physician

  • What is the exact product, and which studies tested it for my condition?
  • Which differences between those studies and my proposed treatment require justification?
  • Is this an approved use, an investigational intervention, or a private-pay service, and in which jurisdiction?
  • How do the expected benefits and risks compare with standard care or no intervention?
  • Who will manage follow-up and complications, including after I return home?

Discuss the answers with a physician familiar with your condition and, where possible, independent of the sale. When arranging care abroad, this guide to evaluating a clinic in Japan provides background on checking the offer and its documentation.

If you are comparing a treatment offer against the checklist above, you can send your questions through our contact page before you decide.

Contact Us

The Bottom Line

Results from one cell type can help frame a research question, but they do not automatically establish another treatment’s effectiveness or safety. Compare the cells, manufacturing, dose, route, condition, and patient population, then assess the study design and follow-up. A mismatch needs evidence and explanation; a match still does not guarantee a personal benefit.

This article provides general information, not medical advice. Discuss treatment options, uncertainties, benefits, and risks with a qualified physician.

References

  1. NIGMS. What Are Stem Cells? November 27, 2024.
  2. National Cancer Institute. Stem Cell Transplants in Cancer Treatment.
  3. Dominici M et al. Minimal criteria for defining multipotent mesenchymal stromal cells: ISCT position statement. Cytotherapy. 2006;8(4):315–317. Laboratory criteria, not evidence of clinical effectiveness.
  4. U.S. FDA. Important Patient and Consumer Information About Regenerative Medicine Therapies. Marked current as of April 8, 2024.
  5. U.S. FDA. FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients. December 18, 2024.
  6. National Cancer Institute. How Do Clinical Trials Work?
  7. Japanese Law Translation. Act on the Safety of Regenerative Medicine.
  8. PMDA. Regenerative Medical Products.